This observational study aims to create a collection of biological samples (like blood, spinal fluid, and urine) from people with Amyotrophic Lateral Sclerosis (ALS) and healthy volunteers. These samples will be linked to genetic information and health records. The goal is to provide these resources to researchers to help them better understand ALS and develop new treatments. The study plans to enroll 1000 participants, including 800 people with ALS and 200 healthy individuals. The main goal is to establish this collection of samples, which will be measured over 3.5 years. You may be eligible if you are 18 or older with a diagnosis of ALS and a lung function (Full Vital Capacity or FVC) of at least 30%.

Study design

This is an observational study involving 1000 participants (800 with ALS, 200 healthy controls). It is not testing a specific drug or intervention.

What's involved

If you have ALS, you would have 5 clinic visits approximately every 4 months. Healthy participants will have 2 study visits with a 12-month break between them. Some participants will also have speech, motor function, and lung function tests every two weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, the biofluid biorepository, will be measured at 3.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.